Navigation Links
New Jersey Health Foundation Initiates Program To Spur Innovative Research
Date:9/10/2012

NEW BRUNSWICK, N.J., Sept. 10, 2012 /PRNewswire-USNewswire/ -- To help advance research in the scientific process, New Jersey Health Foundation is proud to announce the establishment of the New Jersey Health Innovation Stage Funding Program.

Through the new program, $500,000 has been allocated to provide funding in amounts starting at $10,000 up to a maximum of $50,000 each to researchers with promising ideas that may lead to developing patents or intellectual property.  At the current time, researchers with these objectives affiliated with the University of Medicine and Dentistry of New Jersey (UMDNJ) are able to apply for funding.

"New Jersey Health Foundation currently uses its own board-designated assets to support two programs to fund faculty affiliated with UMDNJ," explained Dean Janeway, chairman of the New Jersey Health Foundation Board. "This new program now allows us to fund research that needs investment toward commercialization in all stages—at the very beginning, in the middle stage and toward the end."

Research funding through New Jersey Health starts with the New Jersey Health Annual Grants Program, which has provided more than $50 million in grants to researchers and faculty members since inception of the program.  The grants, up to $40,000 each, provide seed and bridge funding for research projects and education programs. Typically, recipients are researchers who may not yet otherwise be eligible for traditional grant funding. 

"The $50 million that we have awarded through the Annual Grants Program is from our own board-designated funds, which is separate and in addition to money we have raised for research from donors," Mr. Janeway explained.

To support research at a further stage in the process, in 2006 New Jersey Health Foundation established Foundation Venture Capital Group with $5 million to provide investments in emerging medical research and technology being developed by new life science companies. These new companies are at a very early stage in research hoping to move toward commercialization.  The funding provided by FVCG is typically not available to these very early stage companies.  FVCG has invested in eight companies to date.

"During the process of reviewing potential researchers and licensed technology, it became evident that there was a gap in funding between the Annual Grants Program and FVCG investment," noted Dr. George F. Heinrich, vice chair and CEO of New Jersey Health Foundation. "An unmet funding need existed for researchers who are beyond the Annual Grants Program stage but not yet at FVCG investment stage."

For more information, contact Dr. Heinrich at (908) 731-6607 or heinrichmd@njhf.org or James M. Golubieski, president, at (908) 731-6601 or jgolubieski@njhf.org.

About New Jersey Health Foundation
New Jersey Health Foundation (www.njhf.org,) established in 2002 as a not-for-profit public charity, is the parent company to the Foundation of UMDNJ (www.foundationofumdnj.org) and The Foundation for Healthcare Advancement, which solicit private sector support for the University of Medicine and Dentistry of New Jersey and to Foundation Venture Capital Group, LLC,  (www.foundationventure.com) which makes private equity investments in start-up technology companies founded by researchers affiliated with the University.


'/>"/>
SOURCE New Jersey Health Foundation
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Prostate Cancer Center of New Jersey the Latest Center to Achieve High Honor of ACR-ASTRO Accreditation
2. Clinilabs Opens Phase I Unit In Eatontown, New Jersey
3. New Jersey Ophthamologist Now Offers Pelleve Wrinkle Reduction Treatment
4. Dr. Phillip Chan Named Finalist for Ernst & Young Entrepreneur of the Year® 2012 Award in New Jersey
5. Global Pharmaceutical Leaders All Converging in Parsippany, New Jersey on September 11-12, 2012 for Breakthrough Event
6. H. D. Smith Names Timothy Booth Corporate VP, Home Healthcare (HHC), In First-of-its-Kind Leadership Appointment
7. Perrigo Company To Present At The Morgan Stanley Global Healthcare Conference
8. Covance to Present at the Morgan Stanley Global Healthcare Conference
9. Amgen To Present At The Morgan Stanley Global Healthcare Conference
10. Feds Use Tougher Tactics To Fight Healthcare Fraud
11. Jazz Pharmaceuticals Announces Participation At The 2012 Morgan Stanley Global Healthcare Conference In New York On September 11
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... , Dec. 8, 2016 Eli Lilly and ... the neoMONARCH study of abemaciclib, a cyclin-dependent kinase (CDK) ... of reducing expression of Ki67, a biomarker of cell ... the Phase 2 trial presented during the official press ... (SABCS) evaluated abemaciclib, both alone or in combination with ...
(Date:12/7/2016)... Global Cervical Dysplasia Market: Scope and ... dysplasia market analyzes the current and future prospects ... executive summary, including a market snapshot that provides ... The research is a combination of primary and ... our research efforts along with information collected from ...
(Date:12/7/2016)... REPORT OBJECTIVES The report ... intelligence on a market segment, based on geography. ... in the report. The primary objectives of this ... intelligence through detailed segmentation, 2) market size and ... developments, market situation, trends, 3) detailed analysis of ...
Breaking Medicine Technology:
(Date:12/7/2016)... ... December 07, 2016 , ... Children exposed to secondhand marijuana ... the Icahn School of Medicine at Mount Sinai has found. The study was ... children are exposed to secondhand marijuana smoke, measurable amounts of primary metabolite of ...
(Date:12/7/2016)... ... December 07, 2016 , ... Wavelink, ... Device Remote Control through a new partnership with Splashtop Inc. This remote control ... mobile solutions to help businesses maximize their uptime and productivity. , Wavelink offers ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... S.L. (“Presence”) for a purchase price of approximately $17.4 million (net of ... annual revenue is approximately $13.2 million. Headquartered in Barcelona, Spain, Presence is ...
(Date:12/7/2016)... Yorba Linda, Ca (PRWEB) , ... December 07, 2016 , ... ... to attain that funding is with useful, properly analyzed data. The team at Beckman ... generation to address the 'need for speed' and the need to operate in a ...
(Date:12/7/2016)... ... 2016 , ... A quote from Dr. Edward Hallowell, host of CRN International’s ... offer a rare glimpse into the mind of those people with ADHD. , Dr. ... author, has described people with ADHD as having “Ferrari engines for a brain, with ...
Breaking Medicine News(10 mins):